Promote a Clinical Trial


Phase 3 Efficacy Study of AGN-190584 in Participants With Presbyopia

A study to evaluate the efficacy, safety, and pharmacokinetics of AGN-190584 when administered bilaterally, once daily for 30 days in participants with presbyopia.

Sponsored by: Allergan